Antisense oligonucleotides, short synthetic fragments of DNA or RNA, are gaining popularity due to their targeted treatment capabilities in a range of diseases. Leading companies in this field include Ionis Pharmaceuticals with over 40 antisense drugs in its pipeline, Isarna Therapeutics targeting TGF-β in key biological processes, Regulus Therapeutics focusing on microRNAs, Sarepta Therapeutics developing PPMO therapies, Secarna Pharmaceuticals working on therapies for immuno-oncology and fibrotic diseases, and Wave Life Sciences using its proprietary PRISM platform for the development of antisense therapeutics.
HazyBeacon Abuses AWS Lambda Function URLs for Stealthy Command-and-Control Operations
HazyBeacon is a stealthy cloud-native malware campaign identified as CL-STA-1020. It is exploiting Amazon Web Services (AWS) Lambda Function URLs to create covert command-and-control (C2)
